Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss

Journal of Autoimmunity

Volumn 38, Issue 2-3, 2012, Pages

  Martinez de la Torre, Yeny ^a,i   Pregnolato, Francesca ^b   D'Amelio, Fabio ^c   Grossi, Claudia ^b   Di Simone, Nicoletta ^d   Pasqualini, Fabio ^a   Nebuloni, Manuela ^e   Chen, Pojen ^f   Pierangeli, Silvia ^g   Bassani, Niccolò ^c   Ambrogi, Federico ^c   Borghi, Maria Orietta ^b,c   Vecchi, Annunciata ^a   Locati, Massimo ^a,c   Meroni, Pier Luigi ^b,c,h  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f University of Los Angeles   (United States)

^g University of Texas Medical Branch School of Medicine   (United States)

^h ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

ⁱ UNIVERSITY OF CRETE   (Greece)

Author keywords

2 glycoprotein I; Anti phospholipid syndrome; Murine models; Pregnancy complications; TIFI

Indexed keywords

BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY; RNA; SYNTHETIC PEPTIDE; TIFI PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELL FATE; CONTROLLED STUDY; DOWN REGULATION; ECTODERM; EMBRYO DEVELOPMENT; FEMALE; FETUS DEVELOPMENT; FETUS WASTAGE; FETUS WEIGHT; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GROWTH RETARDATION; HISTOGENESIS; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ORGANOGENESIS; PLACENTA WEIGHT; PRIORITY JOURNAL; PROTEIN BINDING; TISSUE DIFFERENTIATION; TROPHOBLAST;

ABORTION, SPONTANEOUS; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; BINDING SITES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, INBRED C57BL; PEPTIDES; PLACENTA; PREGNANCY; PROTEIN BINDING; TROPHOBLASTS;

EID: 84858745359     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.009     Document Type: Article

References (35)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of the antiphospholipid syndrome (APS): understanding the antibodies. Nat Rev Rheumathol 2011, 7:330-339.
3. Meroni P.L., Tedesco F., Locati M., Vecchi A., Di Simone N., Acaia B., et al. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus 2010, 19:453-456.
4. Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospohlipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol; 2011 Nov 10 [Epub ahead of print].
5. Meroni P.L., Gerosa M., Raschi E., Scurati S., Grossi C., Borghi M.O. Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol 2008, 34:332-337.
6. Park A.L. Placental pathology in antiphospholipid syndrome. Hughes' syndrome 2006, 362-374. Springer-Verlag, London. M.A. Khamashta (Ed.).
7. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
8. Berman J., Girardi G., Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485-490.
9. Redecha P., Franzke C.W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008, 118:3453-3461.
10. Girardi G. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clin Rev Allergy Immunol 2010, 39:160-165.
11. Girardi G., Prohászka Z., Bulla R., Tedesco F., Scherjon S. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol 2011, 48:1621-1630.
12. Francis J., Rai R., Sebire N.J., El-Gaddal S., Fernandes M.S., Jindal P., et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006, 12:435-442.
13. Shamonki J.M., Salmon J.E., Hyjek E., Baergen R.N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007, 196:167.e1-167.e5.
14. Cavazzana I., Manuela N., Irene C., Barbara A., Sara S., Orietta B.M., et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. J Autoimmun 2007, 28:160-164.
15. Gerosa M., De Angelis V., Trespidi L., Acaia B., Cetin I., Calabrese S., et al. Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women. Ann Rheum Dis 2009, 68(S3):210.
16. Borghi M.O., Raschi E., Broggini V., Grossi C., D'Amelio F., Chen P., et al. Antiphospholipid antibodies reactivity with human decidual cells: an additional mechanism of pregnancy complications in APS and a potential target for innovative therapeutic intervention. Ann Rheum Dis 2009, 68:109.
17. Martinez de la Torre Y., Buracchi C., Borroni E.M., Dupor J., Bonecchi R., Nebuloni M., et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 2007, 104:2319-2324.
18. Martinez de la Torre Y., Raschi E., Borghi M., Di Simone N., Nebuloni M., Vecchi A., et al. Pregnant naive mice are protected from aPL-induced fœtal loss by the injection of a synthetic peptide (TIFI) mimicking the β2GPI PL-binding site. Arthritis Rheum 2008, 58:S404.
19. Poindron V., Berat R., Knapp A.M., Toti F., Zobairi F., Korganow A.S., et al. Evidence for heterogeneity of the obstetric antiphospholipid syndrome: thrombosis can be critical for antiphospholipid-induced pregnancy loss. J Thromb Haemost 2011, 9:1937-1947.
20. Agostinis C., Biffi S., Garrovo C., Durigutto P., Lorenzon A., Bek A., et al. In vivo distribution of β2 glycoprotein I under various pathophysiological conditions [published online ahead of print Jul 26, 2011]. Blood 2011, 118:4231-4238.
21. Ostertag M.V., Liu X., Henderson V., Pierangeli S.S. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006, 15:358-365.
22. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
23. Zhu M., Olee T., Le D.T., Roubey R.A., Hahn B.H., Woods V.L., et al. Characterization of IgG monoclonal anti-cardiolipin/antiβ2GP1 antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies. Br J Haematol 1999, 105:102-109.
24. Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu X., Colden-Stanfield M., Harris N.E. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002, 46:545-552.
25. Di Simone N., Raschi E., Testoni C., Castellani R., D'Asta M., Shi T., et al. Pathogenic role of anti-beta 2 glycoprotein I antibodies in antiphospholipid-associated fetal loss: characterisation of beta 2 glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2 glycoprotein I antibodies in vitro. Ann Rheum Dis 2005, 64:462-467.
26. Hosack D.A., Dennis G., Sherman B.T., Lane H.C., Lempicki R.A. Identifying biological themes within lists of genes with EASE. Genome Biol 2003, 4:R70.
27. Beissbarth T., Speed T.P. GOstat: find statistically overrepresented gene ontologies within a group of genes. Bioinformatics 2004, 20:1464-1465.
28. Branch W. Obstetric Task Force. Report of the obstetric APS task force: 13th international congress on antiphospholipid antibodies, 13th April 2010. Lupus 2011, 20:158-164.
29. Hoppe B., Burmester G.R., Dörner T. Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). Curr Opin Rheumatol 2011, 23:299-304.
30. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
31. Cowchock F.S., Reece E.A., Balaban D., Branch D.W., Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992, 166:1318-1323.
32. Bramham K., Thomas M., Nelson-Piercy C., Khamashta M., Hunt B.J. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011, 117:6948-6951.
33. Ziakas P.D., Pavlou M., Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010, 115:1256-1262.
34. Ruffatti A., Tonello M., Visentin M.S., Bontadi A., Hoxha A., De Carolis S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology 2011, 50:1684-1689.
35. Di Simone N., Marana R., Castellani R., Di Nicuolo F., D'Alessio M.C., Raschi E., et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 2010, 62:1504-1512.